TY - GEN
T1 - A Phase I Trial of Stereotactic Body Proton Therapy (SBPT) for Liver Metastases
AU - Kang, J.I.
AU - Grove, R.
AU - Hsueh, C.T.
AU - Wroe, A.
AU - Patyal, B.
AU - Reeves, M.E.
AU - Slater, J.D.
AU - Yang, G.Y.
PY - 2016/10
Y1 - 2016/10
N2 - Purpose/Objective(s): To determine the maximum tolerated dose (MTD) of stereotactic body proton therapy (SBPT) for liver metastases in anticipation of a subsequent phase II study. Although phase I studies have shown safety with photon based treatments, similar clinical safety profile and tolerability with proton based therapy has not been reported. Materials/Methods: An IRB approved phase I clinical trial was conducted. Eligible patients had 1-3 liver metastases measuring less than 5cm, and no CNS metastases, tense ascites requiring frequent paracentesis or metastases location within 2cm of the GI tract. The initial cohort received 36 GyE to the planning target volume (PTV) in 3 fractions. Subsequent cohorts received 48 GyE in 3 fractions and finally 60 GyE in 3 fractions, the final chosen maximum dose. At least 700mL of normal liver had to receive
AB - Purpose/Objective(s): To determine the maximum tolerated dose (MTD) of stereotactic body proton therapy (SBPT) for liver metastases in anticipation of a subsequent phase II study. Although phase I studies have shown safety with photon based treatments, similar clinical safety profile and tolerability with proton based therapy has not been reported. Materials/Methods: An IRB approved phase I clinical trial was conducted. Eligible patients had 1-3 liver metastases measuring less than 5cm, and no CNS metastases, tense ascites requiring frequent paracentesis or metastases location within 2cm of the GI tract. The initial cohort received 36 GyE to the planning target volume (PTV) in 3 fractions. Subsequent cohorts received 48 GyE in 3 fractions and finally 60 GyE in 3 fractions, the final chosen maximum dose. At least 700mL of normal liver had to receive
UR - http://linkinghub.elsevier.com/retrieve/pii/S0360301616314419
UR - https://www.mendeley.com/catalogue/b09380ef-ddd6-36fe-99eb-752ad458f0b5/
U2 - 10.1016/j.ijrobp.2016.06.1115
DO - 10.1016/j.ijrobp.2016.06.1115
M3 - Conference contribution
VL - 96
T3 - International Journal of Radiation Oncology Biology Physics
SP - E209
BT - International Journal of Radiation Oncology Biology Physics
ER -